

1 **Reverse mutational scanning of spike BA.2.86 identifies epitopes**

2 **contributing to immune escape from polyclonal sera**

3 Najat Bdeir¹, Tatjana Lüddecke¹, Henrike Maaß¹, Stefan Schmelz², Ulfert Rand³, Henning
4 Jacobsen¹, Kristin Metzdorf¹, Upasana Kulkarni¹, Anne Cossmann⁴, Metodi V. Stankov⁴,
5 Markus Hoffmann^{5,6}, Stefan Pöhlmann^{5,6}, Wulf Blankenfeldt^{2,7}, Alexandra Dopfer-Jablonka^{4,8},
6 Georg M.N. Behrens^{4,8,9#}, Luka Čičin-Šain*^{1,8,9#}

7 ¹ Department of Viral Immunology, Helmholtz Centre for Infection Research, Braunschweig,
8 Germany

9 ² Department Structure and Function of Proteins, Helmholtz Centre for Infection Research
10 Braunschweig, Germany

11 ³DSMZ- German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany

12 ⁴ Department of Rheumatology and Immunology, Hannover Medical School, Hannover,
13 Germany

14 ⁵ Infection Biology Unit, German Primate Center – Leibniz Institute for Primate Research,
15 Göttingen, Germany

16 ⁶ Faculty of Biology and Psychology, University Göttingen, Göttingen, Germany

17 ⁷ Institute for Biochemistry, Biotechnology and Bioinformatics, Technische Universität
18 Braunschweig, Braunschweig, Germany

19 ⁸ German Center for Infection Research, partner site Hannover-Braunschweig, Hannover,
20 Germany

21 ⁹ Centre for Individualized Infection Medicine, a joint venture of HZI and Hannover Medical
22 School, Hannover, Germany

23 # These authors contributed equally *For correspondence: Luka Čičin-Šain: [Luka.Cicin-](mailto:Luka.Cicin-Sain@helmholtz-hzi.de)
24 [Sain@helmholtz-hzi.de](mailto:Luka.Cicin-Sain@helmholtz-hzi.de)

25 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

26 **ABSTRACT**

27 **The recently detected Omicron BA.2.86 lineage contains more than 30 amino acid**
28 **mutations relative to BA.2. BA.2.86 and its JN.1 derivative evade neutralization by serum**
29 **antibodies of fully vaccinated individuals. In this study, we elucidate epitopes driving the**
30 **immune escape of BA.2.86 and JN.1 via pseudovirus neutralization. Thus, we have**
31 **generated 33 BA.2.86 mutants, each reverting a single mutation back to BA.2. We use**
32 **this library in an approach that we call reverse mutational scanning to define distinct**
33 **neutralization titers against each epitope. Mutations within the receptor binding domain**
34 **at K356T, V483 Δ , and to a lesser extent N460K, A484K, and F486P enhance immune**
35 **escape. Interestingly, 16insMPLF within the spike N-terminal domain and P621S within**
36 **S1/S2 also significantly contribute to antibody escape of BA.2.86. Upon XBB.1.5 booster**
37 **vaccination, neutralization titers against JN.1 and BA.2.86 improve considerably, and a**
38 **residual immune escape is driven by 16insMPLF, N460K, E554K, and to a lesser extent**
39 **P621S, and A484K.**

40

41 **EDITOR'S SUMMARY**

42

43 **SARS COV2 Omicron lineage BA.2.86 has over 30 mutations compared to the parental**
44 **BA.2 lineage. Here Bdeir and colleagues apply reverse mutational scanning to**
45 **determine which among these mutations present in Omicron BA.2.86 are epitopes**
46 **linked to immune escape from antibody recognition.**

47

48

49

50

51 INTRODUCTION

52 The emergence of new SARS-CoV-2 virus lineages continues to be a critical aspect of the
53 ongoing epidemic viral spread. Among these lineages, BA.2.86, also known as Pirola, has
54 garnered recent attention owing to its significant antigenic shift away from the prevailing XBB
55 sub-lineage^{2,3}. The earliest detection of BA.2.86 was in late July 2023 in Denmark⁴⁻⁶. By mid-
56 august, it had been detected within several countries and WHO had classified it as a variant of
57 interest⁵⁻⁷. An outbreak of BA.2.86 recorded in the United Kingdom with a high attack rate
58 (86.6%) within an elderly care home demonstrated the transmissibility of this lineage⁸. At
59 present, the extent of disease severity exerted by BA.2.86 is unclear, but its derivative sub-
60 variant JN.1 is on track to become the globally dominant SARS-CoV-2 lineage.

61 The viral spike (S) protein mediates SARS-CoV-2 host cell entry through a multistep process.
62 The initial step involves binding of the S protein to angiotensin converting enzyme-2 receptors
63 (ACE2). This engagement is followed by S protein cleavage by host cell proteases, enabling
64 the S protein to drive fusion of the viral envelope with cellular membranes⁹. The S1 domain
65 of the S protein entails an N-terminal domain (NTD) with somewhat unclear functions, and the
66 receptor-binding domain (RBD), which directly binds to ACE2 and is the major target for
67 neutralizing antibodies⁹⁻¹¹. The transmembrane S2 domain drives viral fusion with the host
68 cell membrane, which facilitates the release of viral genetic material into the cytoplasm, and
69 therefore plays an important role in infection. BA.2.86 harbors more than 30 mutations relative
70 to BA.2, encompassing 13 mutations in NTD, 14 in the RBD, and 7 within the pre S1/S2 and
71 S2 domain¹². Furthermore, several BA.2.86 descendants have been identified, including
72 BA.2.86.1 (defining mutation ORF1a:K1973R), JN.1 (L455S), JN.2 (ORF1a:Y621C), JN.3
73 (ORF1a:T2087I), and BA.2.86.2 (ORF7a:E222D)³.

74 The alarming number of BA.2.86 spike mutations has prompted several efforts to
75 characterize the antibody immune escape potential of this lineage. Recent studies demonstrate

76 reduced pseudo-virus neutralization of BA.2.86 and JN.1 in comparison to BA.2 and B.1
77 strains and that vaccination with the monovalent BNT162b2 XBB.1.5 adapted vaccine
78 significantly enhances neutralization of BA.2.86 pseudo virus by serum antibodies ¹³⁻¹⁵.
79 However, the contribution of single mutations to the immune escape of BA.2.86 remains
80 unclear. Mutational scanning approaches, where libraries of viruses with single amino acid
81 mutations in the spike protein are compared to the wild-type virus are powerful tools for the
82 identification of epitopes recognized by monoclonal antibodies ¹⁶⁻¹⁸, but polyclonal serum
83 antibodies recognize numerous epitopes simultaneously and redundantly. Therefore, mutating
84 one out of 33 epitopes on an ancestral background may only marginally decrease the serum
85 neutralizing activity if some among the remaining 32 epitopes are recognized by independent
86 antibody clones. To overcome this limitation, we cloned a library of 33 reversion mutants on
87 the BA.2.86 background, each harboring a single mutation reverting the position back to the
88 amino acid in BA.2. This approach allowed us to observe a robust increase in neutralizing
89 activity whenever an immunologically relevant epitope was reintroduced in the spike. We
90 tested this library of BA.2.86 mutants against serum samples collected from a cohort of 30
91 healthcare workers, before and after vaccination with the BNT162b2 XBB.1.5 adapted vaccine.
92 Our data showed that mutations ins16MPLF, K356T, N460K, V483Δ, A484K, F486P and
93 S621P distributed across NTD, RBD, and S1/S2 domains, contribute to the immune escape of
94 BA.2.86. Additionally, we show that vaccination with the BNT162b2 XBB.1.5 adapted
95 vaccine increases substantially the neutralization titers against both BA.2.86 and the more
96 recent BA.2.86.1.1 (JN.1) descendant, and that the immune escape of JN.1 is more pronounced
97 than that of BA.2.86 before and after XBB.1.5 booster vaccination. Moreover, we demonstrate
98 that the deletion of the MPLF insertion at position 16, reversions of N460K and K554E, and to
99 lesser extent the reinsertion of the tyrosine residue at position 144, as well as S621P and K484A
100 improve neutralization of BA.2.86 upon the XBB.1.5 booster shot.

101 **RESULTS**

102 **BA.2.86 spike protein harbors a substantial amount of mutations within all domains**

103 The analysis of the BA.2.86 spike sequence (specifically: hCoV-19/Denmark/DCGC-
104 647694/2023, EPI_ISL_18114953) revealed 33 mutations relative to BA.2 spike (Figure 1).
105 These include 13 mutations within the NTD, 14 mutations in the RBD, and 6 mutations within
106 the S2 and pre S1/S2 domain. Of these mutations, there are five deletions (H69 Δ , V70 Δ ,
107 Y144 Δ , N211 Δ , and V483 Δ) and one insertion after V16 (V16insMPLF). Among mutations
108 that have been previously identified in other variants of interest are R21T (B.1.617),
109 H69 Δ /V70 Δ (B.1.1.7/Alpha), Y144 Δ (XBB.1.5; EG.5.1; BA.1), R158G (B.1.617.2/Delta),
110 E484K (B.1.351/Beta; P.1/Gamma) and P681R (B.1.617.2/Delta). Additionally, BA.2.86
111 harbors several mutations, which were rarely reported (V445H, N450D, N481K, V483 Δ ; and
112 E554K)¹⁹⁻²¹. Among these mutations ins16MPLF, Δ Y144, F157S, R158G, H245N, A264D
113 are located within the NTD antigenic supersite and may contribute to immune escape²².
114 Additionally, several mutations within the RBD of BA.2.86 have been associated with antibody
115 resistance including K356T, A484K, and N450D^{10,23,24}, while several other mutations R493Q,
116 F486P, N460K, and V483 Δ may alter ACE2 interactions^{25,26}. Hence, BA.2.86 contains a
117 plethora of mutations within the spike protein, which may alter key properties of this virus in
118 receptor binding and neutralizing antibody escape. To visualize the position of mutations in the
119 spike protein of BA.2.86 with respect to BA.2, we used AlphaFold2/AlphaFold-Multimer^{27,28}
120 to construct a structural model of the spike trimer of BA.2.86. The model, which was obtained
121 in a closed state with respect to the conformation of the RBD, shows that mutations with respect
122 to BA.2 are spread over the distal part of the protein but otherwise do not cluster at specific
123 positions (Fig. 1B-C).

124

125

126

127 **BA.2.86 and JN.1 efficiently escape antibody neutralization**

128 To assess the immune escape of the BA.2.86 and BA.2.86.1.1 (JN.1) lineages, we employed
129 pseudo-virus particles (pp) in neutralization assays. For comparison, we also included particles
130 harboring the spike protein of XBB.1.5 (XBB.1.5_{pp}), Wuhan-Hu-01 (WT_{pp}), BA.1 (BA.1_{pp}),
131 and BA.2 (BA.2_{pp}) (Figure 2A-B). We found that plasma obtained from a cohort of at least
132 double boosted individuals neutralized BA.1_{pp} and BA.2_{pp} 3-fold reduced efficiency as
133 compared to the index WT_{pp}. However, the inhibition of BA.2.86_{pp} and XBB.1.5_{pp} was 57-
134 and 48-fold reduced, respectively (Figure 2A). Antibody escape of JN.1_{pp} was even more
135 pronounced, with a ~141-fold reduction relative to WT_{pp} (Figure 2A). Plasma acquired post
136 vaccination with the XBB.1.5-adapted mRNA vaccine neutralized XBB.1.5_{pp} and BA.2.86_{pp},
137 with almost comparable efficiency, whereby the mean neutralization titer was 9-fold and 11-
138 fold lower than WT_{pp}, respectively, while JN.1_{pp} was 27 fold lower (Figure 2B). Collectively,
139 BA.2.86_{pp} and JN.1_{pp} escaped neutralization by antibodies induced upon primary vaccination
140 series and boosters with immunogens predating XBB lineages, whereby this escape was more
141 pronounced in JN.1. However, a vaccination with the XBB.1.5 adapted vaccine boosted the
142 neutralizing titers against both variants and reduced the gap in neutralization efficiency
143 between them and Omicron BA.2. The neutralization efficiency of JN.1_{pp} was ~2.4 fold
144 reduced relative to BA.2.86_{pp}, before and after XBB.1.5 booster vaccination.

145 **Mutations ins16MPLF, K356T, N460K, V483Δ, A484K, F486P, and P621S contribute to** 146 **BA.2.86 neutralizing antibody escape.**

147 To investigate the effect of individual mutations within BA.2.86 on post-vaccination
148 neutralizing antibody escape, we cloned a comprehensive library of 33 individual BA.2.86
149 mutants. Each of them contains a single reversion relative to the amino acid sequence of BA.2,

150 while retaining the rest of the sequence as in BA.2.86. Geometric means of pseudo-virus
151 neutralization titers (PVNT50) against BA.2.86_{pp} were ~18-fold lower than against BA.2_{pp} prior
152 to vaccination with the XBB.1.5 vaccine (Figure 3A). Hence, we tested which mutations
153 decreased the gap between neutralization of BA.2_{pp} and BA.2.86_{pp}. Our data showed that
154 among the BA.2.86_{pp} mutants with single mutations within the NTD, only the insMPLF16 Δ _{pp}
155 reduced the gap to BA.2_{pp} to a mere 4-fold reduction (Figure 3A). The remaining NTD_{pp} single
156 mutants did not significantly contribute to neutralizing antibody escape, because their
157 neutralization titers were comparable to that of BA.2.86_{pp} (Figure 3B). Moreover, we have
158 shown in Zhang et al, that insMPLF16 Δ leads to a reduction of infectivity in VeroE6 cells²⁹ .
159 Hence, this unique NTD mutation is involved in both immune evasion from sera antibodies
160 and infectivity. While the N-terminus of BA.2.86 spike protein is modelled with lesser
161 confidence than the core of the structure (Figure S1A-C), it is interesting that the N-terminal
162 16MPLF insertion is predicted to interact with a crevice in the N-terminal domain (NTD;
163 Figure S1B-C). This is reminiscent of SARS-CoV spike protein³⁰, albeit here, the N-terminus
164 is yet more extended and anchored via a disulfide bridge to the core of the NTD (Figure S1D).
165 Structural modelling from Colson et. al.³¹ also suggest that insMPLF16 masks a V-shaped
166 electronegative zone within the NTD which might allow an advantage to stabilize the virus on
167 target cells. It may also induce long range conformational rearrangements affecting the RBD
168 and potentially RBD-ACE2 interactions.

169 The neutralization capacity of serum samples against epitopes in the RBD of BA.2.86_{pp} was
170 significantly affected prior to the XBB.1.5 booster by the mutation K356T and Δ V483, which
171 had a 6 or 7 fold reduction in neutralization titer relative to BA.2, respectively (Figure 4A and
172 4B). Additionally, our results showed that K460N_{pp}, K484A_{pp}, and P486F_{pp} had a 6-, 7-, and
173 8-fold reduced neutralization efficiency, respectively, relative to BA.2_{pp}, and thus much less
174 than the 18-fold reduction observed in BA.2.86_{pp}. While the latter results did not raise to

175 statistical significance over BA.2.86_{pp} (Fig. 4B), they indicated an improved neutralization in
176 the presence of these parental epitopes. In contrast, the remaining mutations within the RBD
177 of BA.2.86 did not enhance serum neutralization capacity.

178 In addition to the aforementioned RBD and NTD BA.2.86 mutants, we explored the
179 contribution of mutations within the S1/S2 and S2 regions to antibody evasion. We report a
180 significant increase in neutralization efficiency for BA.2.86 S621P_{pp}, whereby neutralization
181 efficiency of BA.2.86 S621P_{pp} was 4-fold lower than that of BA.2_{pp} and hence, significantly
182 higher than for BA.2.86_{pp} (Figure 5A and 5B) In contrast, BA.2.86 K554E_{pp}, V570A_{pp},
183 R681H_{pp}, F939S_{pp}, L1143P_{pp} all showed comparable neutralization sensitivity as compared to
184 BA.2.86_{pp} (Figure 5A, and 5B).

185 Interestingly, the impact of BA.2.86 mutations on neutralization escape following vaccination
186 with the adapted XBB.1.5 immunogen revealed that the mutants insMPLF16 Δ _{pp}, K554E_{pp}, and
187 K460N_{pp} significantly recovered the neutralization efficiency of plasma samples above
188 BA.2.86_{pp} and to levels comparable to that of BA.2 neutralization (Figure 6). An increase in
189 neutralization efficiency after XBB.1.5 booster vaccination was observed for BA.2.86 mutants
190 S621P_{pp}, ins144Y_{pp} and K484A_{pp}, but it did not raise to statistical significance, (Figure 6).
191 Further information on the post vaccination neutralization titers for each mutant pseudovirus
192 is provided in supplementary data (Figure S2 and Supplementary data 2). Since neutralization
193 efficiency of JN.1_{pp} was merely 2.4 fold reduced relative to BA.2.86_{pp} after the XBB.1.5
194 booster vaccination, our data may argue that these positions may be relevant for the residual
195 immune escape of JN.1 upon the XBB.1.5 booster as well.

196 We previously reported that pseudovirus infectivity of Vero cells was significantly perturbed
197 in Δ ins16MPLF, K403R, D450N, Q493R, and S621P²⁹. Since a reduction in infectivity may
198 reflect an increase of dysfunctional virions in a stock, which would act as sponges for

199 neutralizing antibodies and compete with infectious particles ¹, we performed a digital droplet
200 PCR (ddPCR) of VSV-N stocks, thus defining the genome copy number relative to infectious
201 virus titers. For all tested mutants, these numbers were clustering between those of BA.2 and
202 BA2.86 (Supplementary information, Fig. S3). Therefore, our results all but exclude the
203 possibility that the neutralization titers were affected by the infectivity of the individual epitope
204 mutants.

205 206 **Discussion**

207
208 This work provides to our knowledge the first example of a reverse mutational scanning
209 strategy for the identification of epitopes that contribute to immune escape from vaccine-
210 induced immunity. Strategies based on mutational scanning of the SARS-CoV-2 spike are not
211 new. Others and we have shown that such approaches can be used to generate libraries
212 containing individual mutations present in the Omicron, but not in the ancestral variants, and
213 thus identify epitopes that escape recognition by monoclonal antibodies ^{17,18} and polyclonal
214 sera ^{1,16,17}. A very comprehensive mutational scanning based on the XBB.1.5 spike has been
215 recently performed by the Bloom lab to introduce 9000 theoretical mutations on the XBB.1.5
216 background and thus predict future potential escape mutations ¹⁶. However, forward mutational
217 scanning cannot predict the emergence of lineages with big evolutionary jumps, such as the
218 Omicron BA.1 and BA.2.86 variants, where more than 30 mutations were observed
219 simultaneously, with no intermittent stages that are known. Moreover, such approaches are not
220 ideal for the analysis of neutralizing potential of polyclonal sera, where redundant epitope
221 recognition may result in virus neutralization even if immunologically relevant epitopes are
222 mutated. Indeed, a forward mutational scanning approach that we have employed in a previous
223 study to assess Omicron epitope mutations on a Wuhan background showed only modest
224 (<twofold) reductions in neutralization titers ¹. By reverse mutational scanning, we provide
225 here a loss-of-function genetic approach, allowing the identification of up to fourfold

226 differences in titers. Thus, we were able to identify escape epitopes in polyclonal responses to
227 antigens with many simultaneous mutations, defining the collection of epitopes that contribute
228 to immune escape from vaccine-induced immunity by BA.2.86 and its derivative JN.1 lineage.
229 This approach may also be rapidly deployed for subsequent lineages with big evolutionary
230 jumps that may emerge in the future.

231 The emergence of BA.2.86 harboring more than 30 mutations relative to BA.2 was reminiscent
232 of the Omicron appearance in 2021 and raised concerns regarding its antibody escape potential
233 ^{13,14,32}. A number of these mutations (K356, V445, G446, N450, L452, and P621) were also
234 observed in omicron sub-lineages within immunocompromised patients. This may indicate that
235 reduced immune functions within some individuals may be a source of highly mutated SARS-
236 CoV2 lineages ^{33,34}. BA.2.86 has also evolved several descendants including JN.1 which
237 harbors three mutations in non S-proteins and a hallmark S455L mutation in the spike protein
238 ³. In plasma from a cohort that was at least double boosted, we observed that the S455L
239 mutation reduces the neutralization efficiency relative to BA.2.86 by a factor of ~2.5, but that
240 the XBB.1.5 adapted vaccine booster increases neutralization efficiency against both lineages
241 roughly ~12 to 13 fold, in line with data reported in Stankov et al. ³⁵ and Wang et al. ¹⁴.
242 Moreover, neutralization of BA.2.86_{pp} and JN.1_{pp} were merely 1.2-fold and 3 fold lower than
243 the neutralization of Omicron XBB.1.5 respectively. Nevertheless, their neutralization titers
244 remain 6- and 16 fold lower than that of BA.2 following vaccination respectively.

245 Several mutations within BA.2.86 significantly increased the neutralizing antibody escape
246 prior to vaccination with the adapted XBB.1.5 vaccine. We found that the NTD mutation
247 ins16MPLF significantly affected neutralization sensitivity, and its reversion resulted in a 4-
248 fold increase in neutralization titers relative to BA.2.86. While this region of the NTD is
249 disordered in published structures of the SARS-CoV-2 spike protein, indicating high intrinsic
250 flexibility, the MPLF insertion is somewhat reminiscent of the SARS-CoV spike protein, where

251 the N-terminus is yet more extended and anchored via a disulfide bridge to the core of the NTD
252 (Fig. S1D). It should be noted that several NTD-binding neutralizing antibodies have been
253 identified in the past ^{36,37}, indicating that mutations in this domain may indeed interfere with
254 the immune system's capacity to recognize the virus. Even more interestingly, we show that
255 the deletion of the MPLF insertion at position 16 significantly increases neutralization
256 efficiency after the adapted XBB.1.5 vaccination to BA.2 comparable levels. This mutation is
257 located within the NTD antigenic supersite, which is a key target for NTD specific neutralizing
258 antibodies ²². Moreover, in silico structural modeling of BA.2.86 performed by Colson et al.
259 indicates that the MPLF insertion may mask a V-shaped electronegative zone within the NTD,
260 which is an unprecedented phenotype in SARS-CoV-2. This zone may stabilize the virus onto
261 target cells and may induce some long-range conformational changes which affect the RBD
262 with potential consequences on RBD-ACE2 interactions ³¹. However, our independent in silico
263 analysis of this region of the NTD structure argues that the changes at the N-terminal tip cannot
264 be predicted with a high degree of confidence. Therefore, the actual effects of this mutation on
265 the NTD structure may only be confirmed by empirical analysis in cryoelectron microscopy or
266 similar approaches.

267 We also found that the mutation K356T within the RBD plays a contributing role to
268 BA.2.86 escape of neutralization by polyclonal sera, whereby it lead to a six-fold reduction in
269 neutralization efficiency relative to BA.2_{pp}, in comparison the 18 fold reduction in the case of
270 BA.2.86_{pp}. This reduction in neutralization efficiency might be attributed to the steric hindrance
271 caused by the introduction of an additional glycosylation site ³⁸. Similarly, we show that
272 mutations N460K, V483Δ, A484K, and F486P within the RBD may enhance neutralizing
273 antibody escape. This is in line with reports from Wang et al, which show that mutation N460K
274 and F486P shared in XBB.1.5 and EG.5.1 cause resistance to class 1 and 2 monoclonal
275 antibodies (mAb) ³⁹. Structural modelling has shown that the mutation N460K, which was first

276 identified in BA.2.75, disrupts a hydrogen bond formed between the RBD and a class 1 mAb
277 (VH3-53)⁴⁰ and a study by Wang et al. demonstrated that the mutation A484K within BA.2.86
278 reduced the neutralizing activity of a subset of class 3 mAbs¹⁴. The mutation V483Δ has
279 seldom been reported in circulating strains. Full spike mutational scanning of BA.2.86
280 postulated that V483Δ may contribute to antibody escape but experimental evidence for this
281 has been lacking¹⁶. We also show that the mutation P621S in the S1/S2 domain of BA.2.86
282 contributed to significant neutralization escape and this phenotype, to our knowledge has not
283 been demonstrated previously. In sum, we have identified several mutations that have
284 significantly contributed to immune escape in our cohort. However, we cannot exclude that
285 additional mutations may result in immune escape in individuals whose repertoire differs from
286 our cohort of double boosted individuals. This requires additional studies in cohorts of elderly
287 people or those with immune deficiencies. In parallel to our present study, we have conducted
288 a more thorough investigation to explore the effects of BA.2.86 specific mutations on
289 infectivity and cell entry, including ACE-2 binding and protease usage²⁹. We observed that
290 lung cell entry of BA.2.86 is ACE2 dependent and is markedly more efficient than that driven
291 by the S proteins of other omicron sublineages. To obtain insights into which amino acids are
292 critical to this phenotype, we explored the infectivity of every pseudoviral mutant on Vero and
293 Calu-3 lung cells. This revealed that BA.2.86 specific mutations at NTD residue L50 and RBD
294 residue T356 specifically promote lung cell entry and bear no relevance for Vero cells' entry.
295 Several mutations affected cell entry into Vero cells, up to a sevenfold reduction in infectivity.

296 We have shown previously that mutant viruses with a hundred fold impaired
297 infectiveness display a quantifiable reduction in neutralization serum titers due to the
298 preponderance of non-infectious virus particles in the virus stock that act as antibody sponges
299 in the neutralization assay¹. Thus, we checked if the pseudovirus stocks showing significant
300 differences in the cell entry assay into Vero cells²⁹ or in the neutralization assay had more non-

301 infectious particles (Supplementary information, Fig. S3), but we observed no substantial
302 differences relative to the parental BA.2 or the index BA.2.86 strain. Hence, effects of
303 individual mutations on Vero cell infectivity was unlikely to have affected our neutralization
304 results.

305 It is also important to acknowledge some pertinent limitations relating to our study. We
306 have utilized the well-established pseudo-virus system to assess the contribution of single
307 mutations to the antibody escape potential of BA.2.86. While formal verification would require
308 the use of authentic SARS-CoV-2 with spike mutations introduced by reverse genetics,
309 neutralization titers in pseudo-viral and authentic virus setups have been shown to be
310 comparable due to the immunodominance of spike over other structural elements ⁴¹⁻⁴³. An
311 additional limitation in our study is the lack of information regarding hybrid immunity within
312 our cohort, whereby some participants may have experienced a prior unrecorded infection with
313 XBB sublineages, which may have elicited a humoral immune response similar to vaccination.
314 However, only 4 individuals have a recorded infection in 2023, when the XBB.1.5 lineage was
315 present at high levels.

316 In sum, BA.2.86 and its JN.1 descendent efficiently escape neutralization by polyclonal
317 serum antibodies of at least double boosted individuals, and our data argue that this is due to
318 mutations at positions N460K, V483Δ, A484K, F486P, K356T, P621S, and ins16MPLF. We
319 also observed that the S455L mutation provides a 2-fold decrease in neutralization titers over
320 BA.2.86. However, neutralization titers of JN.1 and BA.2.86 were appreciably improved by
321 the XBB.1.5 vaccine booster, whereby JN.1 has a mere 2.5 reduction relative to BA.2.86 . This
322 may argue that residual immune escape of both lineages may rely on the shared epitopes at
323 positions ins16MPLF, E554K, N460K, and to lesser extent A484K and Y144Δ.

324

325

326 **Methods**

327 **Cell lines**

328 All cell lines were maintained at 37 °C and 5% CO₂ in a humidified environment. 293T (Human,
329 kidney) and VeroE6 (African green monkey, kidney) cells were cultured in Dulbecco's
330 Modified Eagle Medium (DMEM, ThermoFisher Scientific) supplemented with 5% fetal
331 bovine serum (FBS, ThermoFisher Scientific) and 100 U/ml penicillin and 0.1 mg/ml
332 Streptomycin (PAN-Biotec). Both cell lines were used to a maximum passage of 30. For
333 seeding and sub-cultivation, cells were washed with phosphate buffered saline (PBS, PAN-
334 Biotec) and then incubated with trypsin/EDTA (PAN-Biotec) until cell detachment. Cell lines
335 were routinely tested for mycoplasma. The origin and catalogue numbers of cells are shown in
336 table 1, Supplementary data 3. Transfection of 293T cells for the production of pseudoviruses
337 was carried out by calcium phosphate transfection.

338 **Plasmids**

339 The plasmid pCG1_SARS-2-Sdel18 (Codon-optimized) encoding the spike protein of the
340 Wuhan-Hu-1 SARS-CoV-2 has been previously reported ⁹. The pCG1_SARS-2-Sdel18 BA.1
341 and BA.2 expression plasmids are previously reported ¹ and based on isolate hCoV-
342 19/Botswana/R40B58_BHP_3321001245/2021 (GISAID Accession ID: EPI_ISL_6640919)
343 and isolate hCoV-19/England/PHEC-4G0AFZF7/2021 (GISAID Accession ID:
344 EPI_ISL_8738174) respectively. The pCG1_SARS-2-Sdel18 XBB expression plasmid was
345 generated by Gibson assembly based on the expression vector for the spike of Omicron BA.2
346 and site directed mutagenesis was done to generate XBB.1.5. Expression plasmids pCAGGS-
347 DsRed and pCG1-SARS-2-SDel18 BA.2.86 (based on the isolate hCoV-19/Denmark/DCGC-
348 647694/2023, EPI_ISL_18114953) were kindly provided by the Laboratory of Stefan
349 Pöhlmann (Table 3, Supplementary data 3). Site directed mutagenesis (Q5® High-Fidelity 2X
350 Master Mix, New England BioLabs) was utilized for the generation of the SARS-CoV-2 spike

351 BA.2.86 expression plasmid library containing single point mutations back to BA.2 spike.
352 Transformation was carried out using NEB® 10-beta Competent E. coli from New England
353 BioLabs (catalogue: C3019H). Primers are listed in Table 2, Supplementary data 3.

354

355 **Production and titration of Pseudo-viruses**

356 Production of pseudo-viruses was performed according to published protocol ⁴⁴. In brief, 293T
357 cells were seeded in 6 well plates at a confluency of 70%. The next day, cells were transfected
358 with expression plasmids for pCG1-SARS-2-SΔ18 WT,
359 pCG1-SARS-2-SΔ18 BA2.86, pCG1-SARS-2-SΔ18 BA2, pCG1-SARS-2-SΔ18 BA2.86
360 XBB or pCG1-SARS-2-SΔ18 BA2.86 single point mutants. At 24 hours post transfection, cells
361 were incubated for 1 hour with a replication deficient VSV (VSV*ΔG) expressing enhanced
362 green fluorescent protein (eGFP) and firefly luciferase at an MOI of 3. VSV*ΔG was kindly
363 provided by the lab of Gert Zimmer. Subsequently, cells were washed with phosphate buffered
364 saline (PBS) and incubated with anti-VSV-G antibody (mouse hybridoma supernatant from
365 CRL-2700; ATCC) in order to neutralize residual input virus. At 12 hours post infection,
366 supernatants were harvested and cleared from cell debris by centrifugation and stored at -80C
367 for later use. For titration, aliquots of the pseudo-virus were serially diluted threefold in
368 duplicates, starting with a 1:10 dilution in a 96-well plate, totaling eleven dilutions. The last
369 column served as a control with cells but no pseudo-virus. Confluent VeroE6 cells in the 96-
370 well format were infected with the diluted virus, then incubated for 24 hours at 37°C with 5%
371 CO₂. GFP+ infected cells were counted using the IncuCyte S3 (Sartorius), which performed
372 whole-well scans (4x) in phase contrast and green fluorescence (300ms exposure). The
373 IncuCyte GUI software (versions 2019B Rev1 and 2021B) was used for counting of fluorescent
374 foci and counts were exported to Excel 2016. The average number of infected cells was
375 calculated for three different pseudo-virus dilutions, and this number was multiplied by the

376 dilution factor to determine the focus forming units (ffu) per ml. The pseudo-virus titer was
377 calculated as the mean ffu/ml from the three pseudo-virus dilutions.

378

379 **Neutralization assay**

380 Neutralization assays were based on a previously published protocol ¹. In brief, all plasma
381 samples utilized in this study were heat inactivated at 56 °C for 30 minutes, 10 fold diluted in
382 DMEM [1% Penicillin-Streptomycin, 1% L-Glu, 5% FBS], and stored at 4 °C for further use.
383 Pseudo-viral particles (600pfu/well± 30%) were incubated for one hour in a 96 well microtiter
384 plate with two-fold diluted serum samples in DMEM [1% Penicillin-Streptomycin, 1% L-Glu,
385 5% FBS] ranging from 1:100 to 1:51200. Pseudo-virus particles were incubated in the absence
386 of plasma as controls indicating 0% inhibition. After incubation, the serum/virus samples were
387 transferred onto a confluent VeroE6 96 well plate. After a 24-hour incubation, plates were fixed
388 with 4% paraformaldehyde (PFA) and stored at 4 °C until readout. GFP+ infected cells were
389 counted using an IncuCyte S3 (Sartorius) performing whole-well scans (4x) in phase contrast
390 and green fluorescence settings (300ms exposure). Automated segmentation and counting of
391 fluorescent foci defined as green fluorescent protein GFP+-single cells was performed using
392 the IncuCyte GUI software (versions 2019B Rev1 and 2021B). Pseudo-virus neutralization
393 titer 50 (PVNT50) values were determined by a non-linear regression model. The lower limit
394 of confidence (LLOC) was set at a PVNT50 of 50. Non-responders were defined as individuals
395 with PVNT50<60 (dashed line). All PVNT50<10 are set at 10 for visualization purposes. Due
396 to technical limitations (the limited volume of plasma samples and the technical challenges
397 associated with assaying 30 samples against ~40 different pseudoviruses in duplicates), every
398 pseudovirus was tested on at least 20 individual, randomly chosen plasma samples. These were
399 arranged so that over 80% of the plasma originated from the same set of patients. This approach

400 aimed to minimize variability due to differing inherent potencies among plasma samples. All
401 data are presented as numerical titers for each study participant in the supplementary data 2.

402

403 **Ethics committee Approval**

404 The collection of all plasma samples was approved by the research ethics committee of the
405 Institutional Review Board of Hannover Medical School (8973_BO_K_2020). All donors
406 provided written consent for plasma donation and use research purposes, consent for publishing
407 identifiers such as sex and age was also acquired.

408 **Plasma Samples**

409 The number of participants within this analysis is n=30. Median age is 45 years (interquartile
410 range (IQR) 33 to 56). Male to female ratio is 1:2. Among these participants, 30% were
411 vaccinated with three vaccine doses, 60% were vaccinated with four vaccine doses, and 10%
412 were vaccinated with more than four doses. Ten participants (33.3%) were vaccinated with the
413 bivalent WT/BA.4/5 vaccine. The median time in months since last recorded SARS-CoV-2
414 infection for the patients with known infections is 15 (IQR 13 to 18). The median number of
415 months since the last known vaccination dates within our cohort is 13,5 months (IQR 11 to 22).
416 All participants are part of the COVID-19 contact study, to monitor anti-SARS-CoV-2 immune
417 responses in healthcare workers at Hannover Medical School (MHH). All participants donated
418 blood directly prior to vaccination with 30µg of the updated BNT162b2 Omicron XBB.1.5
419 vaccine (Raxtozinameran, BioNTech, Mainz, Germany) in September 2023 and were
420 followed-up for another blood collection 15-16 days post vaccination³⁵. Plasma was separated
421 from collected blood and stored at -80 °C for long term storage and 4°C for immediate use.
422 Detailed information is provided in Supplementary data 1.

423

424

425 **Viral genome copy number**

426 To quantify the VSV genome copy numbers in samples, digital droplet PCR (ddPCR) was
427 performed on the VSV-N gene. Supernatants containing viral particles were treated with
428 nuclease muncher (Abcam) by incubating with 2 U/ml for >60 min at 37°C before RNA
429 isolation using the QIAamp Viral RNA Mini kit according to the manufacturer's instructions.
430 For ddPCR, a one-step RT-ddPCR kit (Bio-Rad) was used combined with primers and probe
431 detecting the VSV N (qRT VSV-N_F: ATGACAAATGGTTGCCTTTGTATCTACTT,
432 qRT VSV-N R: ACGACCTTCTGGCACAAGAGGT, VSV-NcDNA probe:
433 /56FAM/ACAGAGTGG/ZEN/GCAGAACACAAATGCCT/3IABkFQ/) and, to exclude the
434 presence of non-enveloped RNA in the sample, we used the human ACTB transcript
435 (ACTBcDNA_F: GAGGAGCACCCCGTG, ACTBcDNA_R: GCCTGGATAGCAACGTAC,
436 ACTBcDNA_probe: [HEX]CCCAGATCATGTTTGAGACCTTCAACACC[BHQ1]) PCR
437 was done with a Bio-Rad C1000 Touch thermo cycler, encapsulation and read-out were done
438 with the Bio-Rad QX200 system. Data analysis was carried out with Bio-Rad QX Manager
439 Standard Edition (version 2.1.0.25).

440

441 **Statistical analysis**

442 Statistical analysis was performed using GraphPad Prism 9.0 (GraphPad software).
443 Neutralization titers were plotted as geometric mean titers. A two sided paired non-parametric
444 Friedman test was performed for non-normally distributed data. P values less than 0.05 were
445 considered significant ns, $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$).

446 **Data availability**

447 Values for neutralization titers and information on plasma donors are provided in
448 Supplementary data 1 and 2. Data underlying the generation of the figures are provided as a
449 source data file: Source Data.

450 References

- 451 1 Katzmarzyk, M. *et al.* Systematical assessment of the impact of single spike
452 mutations of SARS-CoV-2 Omicron sub-variants on the neutralization capacity of
453 post-vaccination sera. *Front Immunol* **14**, 1288794, doi:10.3389/fimmu.2023.1288794
454 (2023).
- 455 2 Callaway, E. Why a highly mutated coronavirus variant has scientists on alert. *Nature*
456 **620**, 934, doi:10.1038/d41586-023-02656-9 (2023).
- 457 3 Focosi, D., Spezia, P. G. & Maggi, F. SARS-CoV-2 BA.2.86 ("Pirola"): Is it Pi or
458 Just Another Omicron Sublineage? *Vaccines (Basel)* **11**,
459 doi:10.3390/vaccines11111634 (2023).
- 460 4 Harris, E. CDC Assesses Risk From BA.2.86, Highly Mutated COVID-19 Variant.
461 *Jama* **330**, 1029, doi:10.1001/jama.2023.16105 (2023).
- 462 5 Rasmussen, M. *et al.* First cases of SARS-CoV-2 BA.2.86 in Denmark, 2023. *Euro*
463 *Surveill* **28**, doi:10.2807/1560-7917.Es.2023.28.36.2300460 (2023).
- 464 6 Wannigama, D. L. *et al.* Tracing the new SARS-CoV-2 variant BA.2.86 in the
465 community through wastewater surveillance in Bangkok, Thailand. *Lancet Infect Dis*
466 **23**, e464-e466, doi:10.1016/s1473-3099(23)00620-5 (2023).
- 467 7 Lambrou, A. S. *et al.* Early Detection and Surveillance of the SARS-CoV-2 Variant
468 BA.2.86 - Worldwide, July-October 2023. *MMWR Morb Mortal Wkly Rep* **72**, 1162-
469 1167, doi:10.15585/mmwr.mm7243a2 (2023).
- 470 8 Reeve, L. *et al.* High attack rate in a large care home outbreak of SARS-CoV-2
471 BA.2.86, East of England, August 2023. *Euro Surveill* **28**, doi:10.2807/1560-
472 7917.Es.2023.28.39.2300489 (2023).
- 473 9 Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and
474 Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280.e278,
475 doi:10.1016/j.cell.2020.02.052 (2020).
- 476 10 Lusvardi, S. *et al.* Key Substitutions in the Spike Protein of SARS-CoV-2 Variants
477 Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can
478 Modify the Effects. *J Virol* **96**, e0111021, doi:10.1128/jvi.01110-21 (2022).
- 479 11 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable
480 bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
- 481 12 Yang, S. *et al.* Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.
482 *Lancet Infect Dis* **23**, e457-e459, doi:10.1016/s1473-3099(23)00573-x (2023).
- 483 13 Uriu, K. *et al.* Transmissibility, infectivity, and immune evasion of the SARS-CoV-2
484 BA.2.86 variant. *Lancet Infect Dis* **23**, e460-e461, doi:10.1016/s1473-3099(23)00575-
485 3 (2023).
- 486 14 Wang, Q. *et al.* Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike.
487 *Nature*, doi:10.1038/s41586-023-06750-w (2023).
- 488 15 Qian, W. *et al.* XBB.1.5 monovalent mRNA vaccine booster elicits robust
489 neutralizing antibodies against emerging SARS-CoV-2 variants. *bioRxiv*,
490 2023.2011.2026.568730, doi:10.1101/2023.11.26.568730 (2023).
- 491 16 Dadonaite, B. *et al.* Full-spike deep mutational scanning helps predict the
492 evolutionary success of SARS-CoV-2 clades. *bioRxiv*,
493 doi:10.1101/2023.11.13.566961 (2023).
- 494 17 Pastorio, C. *et al.* Determinants of Spike infectivity, processing, and neutralization in
495 SARS-CoV-2 Omicron subvariants BA.1 and BA.2. *Cell Host Microbe* **30**, 1255-
496 1268.e1255, doi:10.1016/j.chom.2022.07.006 (2022).

- 497 18 Abassi, L. *et al.* Evaluation of the Neutralizing Antibody STE90-C11 against SARS-
498 CoV-2 Delta Infection and Its Recognition of Other Variants of Concerns. *Viruses* **15**,
499 doi:10.3390/v15112153 (2023).
- 500 19 Miller, J. *et al.* Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants
501 BQ.1.1 and XBB.1. *N Engl J Med* **388**, 662-664, doi:10.1056/NEJMc2214314 (2023).
- 502 20 Yue, C. *et al.* ACE2 binding and antibody evasion in enhanced transmissibility of
503 XBB.1.5. *Lancet Infect Dis* **23**, 278-280, doi:10.1016/s1473-3099(23)00010-5 (2023).
- 504 21 Wang, Q. *et al.* Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1,
505 BA.4 and BA.5. *Nature* **608**, 603-608, doi:10.1038/s41586-022-05053-w (2022).
- 506 22 McCallum, M. *et al.* N-terminal domain antigenic mapping reveals a site of
507 vulnerability for SARS-CoV-2. *Cell* **184**, 2332-2347.e2316,
508 doi:10.1016/j.cell.2021.03.028 (2021).
- 509 23 Vellas, C. *et al.* Resistance mutations in SARS-CoV-2 omicron variant in patients
510 treated with sotrovimab. *Clin Microbiol Infect* **28**, 1297-1299,
511 doi:10.1016/j.cmi.2022.05.002 (2022).
- 512 24 Mykytyn, A. Z., Fouchier, R. A. & Haagmans, B. L. Antigenic evolution of SARS
513 coronavirus 2. *Curr Opin Virol* **62**, 101349, doi:10.1016/j.coviro.2023.101349 (2023).
- 514 25 Huo, J. *et al.* A delicate balance between antibody evasion and ACE2 affinity for
515 Omicron BA.2.75. *Cell Rep* **42**, 111903, doi:10.1016/j.celrep.2022.111903 (2023).
- 516 26 Qu, P. *et al.* Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75
517 variant. *Cell Host Microbe* **30**, 1518-1526.e1514, doi:10.1016/j.chom.2022.09.015
518 (2022).
- 519 27 Tunyasuvunakool, K. *et al.* Highly accurate protein structure prediction for the human
520 proteome. *Nature* **596**, 590-596, doi:10.1038/s41586-021-03828-1 (2021).
- 521 28 Richard, E. *et al.* Protein complex prediction with AlphaFold-Multimer. *bioRxiv*,
522 2021.2010.2004.463034, doi:10.1101/2021.10.04.463034 (2022).
- 523 29 Zhang, L. *et al.* SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing
524 antibodies with high efficiency. *Cell* **187**, 596-608.e517,
525 doi:10.1016/j.cell.2023.12.025 (2024).
- 526 30 Yuan, Y. *et al.* Cryo-EM structures of MERS-CoV and SARS-CoV spike
527 glycoproteins reveal the dynamic receptor binding domains. *Nat Commun* **8**, 15092,
528 doi:10.1038/ncomms15092 (2017).
- 529 31 Colson, P. *et al.* Emergence of a second SARS-CoV-2 variant with a tremendous
530 genetic leap from its ancestors. *J Med Virol* **95**, e29124, doi:10.1002/jmv.29124
531 (2023).
- 532 32 Sheward, D. J. *et al.* Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing
533 neutralising antibody responses. *Lancet Infect Dis* **23**, e462-e463, doi:10.1016/s1473-
534 3099(23)00588-1 (2023).
- 535 33 Berkhout, B. & Herrera-Carrillo, E. SARS-CoV-2 Evolution: On the Sudden
536 Appearance of the Omicron Variant. *J Virol* **96**, e0009022, doi:10.1128/jvi.00090-22
537 (2022).
- 538 34 Raglow, Z. *et al.* SARS-CoV-2 shedding and evolution in immunocompromised hosts
539 during the Omicron period: a multicenter prospective analysis. *medRxiv*,
540 doi:10.1101/2023.08.22.23294416 (2023).
- 541 35 Stankov, M. V. *et al.* Humoral and cellular immune responses following BNT162b2
542 XBB.1.5 vaccination. *Lancet Infect Dis*, doi:10.1016/s1473-3099(23)00690-4 (2023).
- 543 36 Chi, X. *et al.* A neutralizing human antibody binds to the N-terminal domain of the
544 Spike protein of SARS-CoV-2. *Science* **369**, 650-655,
545 doi:doi:10.1126/science.abc6952 (2020).

- 546 37 Suryadevara, N. *et al.* An antibody targeting the N-terminal domain of SARS-CoV-2
547 disrupts the spike trimer. *J Clin Invest* **132**, doi:10.1172/jci159062 (2022).
- 548 38 Wang, Q. *et al.* Evolving antibody evasion and receptor affinity of the Omicron
549 BA.2.75 sublineage of SARS-CoV-2. *iScience* **26**, 108254,
550 doi:10.1016/j.isci.2023.108254 (2023).
- 551 39 Wang, Q. *et al.* Alarming antibody evasion properties of rising SARS-CoV-2 BQ and
552 XBB subvariants. *Cell* **186**, 279-286.e278, doi:10.1016/j.cell.2022.12.018 (2023).
- 553 40 Wang, Q. *et al.* Antigenic characterization of the SARS-CoV-2 Omicron subvariant
554 BA.2.75. *Cell Host Microbe* **30**, 1512-1517.e1514, doi:10.1016/j.chom.2022.09.002
555 (2022).
- 556 41 Lester, S. *et al.* Middle East respiratory coronavirus (MERS-CoV) spike (S) protein
557 vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable
558 alternative to the conventional neutralization assay in human seroepidemiological
559 studies. *Access Microbiol* **1**, e000057, doi:10.1099/acmi.0.000057 (2019).
- 560 42 Tolah, A. M. K. *et al.* Evaluation of a Pseudovirus Neutralization Assay for SARS-
561 CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay.
562 *Diagnostics (Basel)* **11**, doi:10.3390/diagnostics11060994 (2021).
- 563 43 Quandt, J. *et al.* Omicron BA.1 breakthrough infection drives cross-variant
564 neutralization and memory B cell formation against conserved epitopes. *Sci Immunol*
565 **7**, eabq2427, doi:10.1126/sciimmunol.abq2427 (2022).
- 566 44 Berger Rentsch, M. & Zimmer, G. A vesicular stomatitis virus replicon-based
567 bioassay for the rapid and sensitive determination of multi-species type I interferon.
568 *PLoS One* **6**, e25858, doi:10.1371/journal.pone.0025858 (2011).
- 569 45 Jumper, J. *et al.* Highly accurate protein structure prediction with AlphaFold. *Nature*
570 **596**, 583-589, doi:10.1038/s41586-021-03819-2 (2021).
- 571

572

573

574

575

576

577

578

579

580

581

582

583

584 **ACKNOWLEDGEMENTS:**

585 This research was funded by the Helmholtz Association through Helmholtz Campaign
586 COVIPA (KA1-Co-02) to L.C-S. and EU-Partnering grant MCMVaccine (PIE-008) to L.C-S.
587 and S.P. Funding to L.C-S and S.P. was also provided by the Ministry of Science and Culture
588 of Lower Saxony, through the COFONI Network, flex fund projects 6FF22 and 10FF22. L.C-
589 S also obtained funding from the German Scientific Foundation (DFG) through grants EXC
590 2155 “RESIST”—Project ID 39087428 and FOR2830, project 5.

591 G.M.N.B. and A.D.-J. acknowledge funding from Ministry of Science and Culture of Lower
592 Saxony (14-76103-184, COFONI Network, project 4LZF23), G.M.N.B. acknowledges
593 funding by the European Regional Development Fund (ZW7-85151373), and A.D.-J.
594 acknowledge funding by European Social Fund (ZAM5-87006761).

595 We thank Ayse Barut, Yuliia Polianska, Inge Hollatz-Rangosch and Karina Watzke for expert
596 technical assistance, Natascha Gödecke for support with biosafety compliance and Gert
597 Zimmer (Institute of Virology and Immunology, Mittelhäusern, Switzerland) for providing the
598 VSV pseudo-virus system. We also thank the CoCo Study participants for their support and
599 the entire CoCo study team, especially Annika Heidemann and Luis Manthey, for technical
600 and logistical support.

601 **AUTHOR CONTRIBUTIONS**

602 Conceptualization: LC-S; Methodology: LC-S; NB; Investigation: NB, TL, HM, KM, HJ, SS.
603 UK, UR; Formal analysis: NB, SS, WB, UR, AD-J, GMN, LC-S; Resources: SP, MH,
604 AC,MVS, AD-J, and GMN; Funding acquisition: LC-S; Writing original draft: NB.; Writing
605 review & editing: all authors.

606 **COMPETING INTERESTS**

607 L.C-S. served as an advisor to Sanofi unrelated to this work. G.M.N.B. served as advisor for
608 Moderna unrelated to this work, A.D-J served as an advisor for Pfizer unrelated to this work,

609 S.P. and M.H. conducted contract research (testing of vaccinee plasma for neutralizing activity
610 against SARS-CoV-2) for Valneva unrelated to this work. S.P. served as advisor for BioNTech,
611 unrelated to this work. H.J. served as advisor on COVID neutralization assays for WHO and
612 CEPI, unrelated to this work. The other authors declare no competing interests.

613

614

615 FIGURES LEGENDS

616

617 **Figure 1. Overview of BA.2.86 lineage specific spike protein mutations relative to BA.2**

618 (A) Schematic representation of the SARS-CoV-2 spike domains and amino acid changes
619 indicated for BA.2.86, and shared by XBB.1.5, and EG.5.1 compared to the spike of BA.2.

620 Further mutations within XBB.1.5 and EG.5.1 relative to BA.2 are not shown, as only sites

621 mutated within BA.2.86 are represented. N-terminal domain (NTD, blue), receptor binding

622 domain (RBD, green), Subdomains 1 and 2 (SD1 and SD2, orange), S2 subunit (orange).

623 Created in BioRender. Bdeir, N. (2024) BioRender.com/m05k539 and in the references add:

624 Bdeir, N. (2024). Figure 1A. Created in BioRender. BioRender.com/m05k539. (B) Model of

625 the trimeric spike protein of BA.2.86, calculated with AlphaFold2/AlphaFold-Multimer^{28,45}.

626 The N-terminal secretion signal (15 residues) and the C-terminal membrane-anchoring

627 sequence (112 residues) were omitted from calculations, leading to 3372 residues in the final

628 model. Domains have been colored according to panel (A), and one of five independently

629 calculated models is shown. Spheres represent the location of mutations with respect to the

630 spike protein of BA.2. The positions of deletions are colored in green, red spheres indicate

631 mutations that lead to enhanced immune escape of BA.2.86, other mutations are shown in blue.

632 For clarity, mutations are only shown in one chain of the spike trimer. (C) Magnified view of

633 one trimer extracted from the model shown in (B) and shown in the same orientation.

634

635

636 **Figure 2. BA.2.86 and JN.1 efficiently evade neutralization in double boosted**
637 **individuals, but the adapted XBB.1.5 vaccine booster enhances protection against both.**

638 (A) Particles pseudo-typed with the indicated S proteins were pre-incubated for one hour at
639 37 °C with plasma dilutions from double boosted health care workers (biological replicates
640 n=30) (2A) or with plasma dilutions following vaccination with an adapted XBB.1.5 booster
641 (biological replicates n=30) (2B). Pseudo-virus neutralization titer 50 (PVNT50) was
642 calculated using the least squares fit using a variable slope, using a four-parameter nonlinear
643 regression model and values were plotted as geometric mean. Geometric mean standard
644 deviation bars are shown in black. The lower limit of confidence (LLOC) was set at a PVNT50
645 of 50. Non responders are defined as individuals below 60 (dashed line). All PVNT50 below
646 10 are set at 10 for visualization purposes. The assay was performed in technical duplicates
647 and with negative controls to assess the virus input of each used pseudo-virus in the absence
648 of plasma antibodies. Percentage of positive responders, geometric means, and fold change
649 neutralization over WT-Wuhan_{pp} are shown on top. Friedman two sided non parametric paired
650 test (ns, $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$). Percentage of positive responders,
651 geometric means, and fold change neutralization over WT-Wuhan_{pp} are shown on top. Source
652 data are provided as a Source Data file.

653

654 **Figure 3. Mapping mutations in the NTD for effects of BA.2.86 neutralization efficiency**
655 **in double boosted individuals**

656 (A) Neutralization assessment for particles pseudo-typed with mutations within the NTD of
657 BA.2.86. Each mutant shown contains a single mutation reverting the amino acid mutation in
658 BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the
659 indicated S proteins were preincubated for one hour at 37 °C with plasma dilutions from double

660 boosted health care workers with non-adapted immunogens . The numbers of biological
661 replicates corresponding to individual plasma samples are shown on top. Pseudo-virus
662 neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable
663 slope, using a four-parameter nonlinear regression model. The lower limit of confidence
664 (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below 60
665 (dashed line) All PVNT50 below 10 are set at 10 for visualization purposes. The assay was
666 performed in technical duplicates and with negative controls to assess the virus input of each
667 used pseudo-virus in the absence of plasma antibodies. Percentage of positive responders,
668 geometric means, and fold change neutralization over WT-Wuhan_{pp} are shown on top.
669 Geometric mean standard deviation bars are shown in black. (B) Individual neutralization data
670 for particles pseudo-typed with mutations within the NTD of BA.2.86. Statistical significance
671 was assessed by Friedman two sided non parametric paired test (ns, $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$;
672 ***, $p \leq 0.001$). Source data are provided as a Source Data file.

673

674 **Figure 4. Mapping mutations in the RBD for effects of BA.2.86 neutralization efficiency**
675 **in double boosted individuals**

676

677 (A) Neutralization assessment for particles pseudo-typed with mutations within the RBD of
678 BA.2.86. Each mutant shown contains a single mutation reverting the amino acid mutation in
679 BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with the
680 indicated S proteins were pre-incubated with serum dilutions from immunized health care
681 workers for one hour at 37 °C. The numbers of biological replicates corresponding to individual
682 plasma samples are shown on top. The lower limit of confidence (LLOC) was set at a PVNT50
683 of 50. Non responders are defined as individuals below 60 (dashed line). Non responders are
684 defined as individuals below this threshold. All PVNT50 below 10 are set at 10 for

685 visualization purposes. The assay was with negative controls to assess the virus input of each
686 used pseudo-virus in the absence of plasma antibodies. Percentage of positive responders,
687 geometric means, and fold change neutralization over BA.2_{pp} are shown on top. Geometric
688 mean standard deviation bars are shown in black. (B) Individual neutralization data for particles
689 pseudo-typed with mutations within the RBD of BA.2.86. Statistical significance was assessed
690 by Friedman two sided non parametric paired test (ns, $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$; ***,
691 $p \leq 0.001$). Source data are provided as a Source Data file.

692

693 **Figure 5. Mapping mutations in the S1/S2 domain for effects of BA.2.86 neutralization**
694 **efficiency in double boosted individuals**

695

696 (A) Neutralization assessment for particles pseudo-typed with mutations within the S1/S2 and
697 S2 domain of BA.2.86. Each mutant shown contains a single mutation reverting the amino acid
698 mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with
699 the indicated S proteins were preincubated for one hour at 37 °C with plasma dilutions from
700 double boosted health care workers with non-adapted immunogens. The numbers of
701 biological replicates corresponding to individual plasma samples are shown on top. Pseudo-
702 virus neutralization titer 50 (PVNT50) was calculated using the least squares fit using a variable
703 slope, using a four-parameter nonlinear regression model. The lower limit of confidence
704 (LLOC) was set at a PVNT50 of 50. Non responders are defined as individuals below 60
705 (dashed line). All PVNT50 below 10 are set at 10 for visualization purposes. The assay was
706 performed with negative controls to assess the virus input of each used pseudo-virus in the
707 absence of plasma antibodies. Percentage of positive responders, geometric means, and fold
708 change neutralization over BA.2_{pp} are shown on top. Geometric mean standard deviation bars
709 are shown in black. (B) Individual neutralization data for particles pseudo-typed with mutations

710 within the S1/S2 and S2 domain of BA.2.86. Statistical significance was assessed by Friedman
711 two sided nonparametric paired test (ns, $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$).
712 Source data are provided as a Source Data file.

713




714 **Figure 6: Reversions insMPLF16 Δ , K460N, K554E and to lesser extent insY144, K484A,**
715 **and S621P enhance the neutralization efficiency of plasma samples post BNT162b2**
716 **XBB.1.5 vaccination.**

717 (A-F) Neutralization assessment for pseudo-typed particles with plasma post BNT162b2
718 XBB.1.5 vaccination. Each mutant shown contains a single mutation reverting the amino acid
719 mutation in BA.2.86 to the corresponding amino acid within BA.2. Particles pseudo-typed with
720 the indicated S proteins were pre-incubated for one hour at 37 °C with plasma dilutions from
721 double boosted health care workers. Pseudo-virus neutralization titer 50 (PVNT50) was
722 calculated using the least squares fit using a variable slope, using a four-parameter nonlinear
723 regression model. The lower limit of confidence (LLOC) was set at a PVNT50 of 50. Non
724 responders are defined as individuals below this 60 (dashed line). .All PVNT50 below 10 are
725 set at 10 for visualization purposes. The assay was performed in technical duplicates and with
726 negative controls to assess the virus input of each used pseudo-virus in the absence of plasma
727 antibodies. Statistical significance was assessed by Friedman two sided nonparametric paired
728 test (ns, $p > 0.05$; *, $p \leq 0.05$; **, $p \leq 0.01$; ***, $p \leq 0.001$). Source data are provided as a
729 Source Data file.

730


731

SARS-CoV2 spike




A) Before XBB.1.5 booster vaccination

Response rate:	100%	100%	100%	60%	63%	37%
Geometric mean titer:	5375	1847	1646	113	94	38
Fold reduction (vs.WT):	—	3	3	48	57	141



B) After XBB.1.5 booster vaccination


Response rate:	100%	100%	100%	96.6%	96.6%	76.6%
Geometric mean titer:	13517	8569	7969	1467	1280	493
Fold change (vs.WT):	—	2	2	9	11	27




Neutralisation titers for NTD specific BA.2.86pp mutants pre XBB.1.5 adapted vaccine

A)

Geometric mean titer:	1646	94	453	107	60	100	102	85	87	131	112	135	171	122	88
Fold reduction (vs. BA.2):	—	18	4	15	27	16	16	19	19	13	15	12	10	13	19
Sample number:	30	30	21	25	25	18	20	19	19	20	20	21	20	20	23





B)



Neutralisation titers for RBD specific BA.2.86pp mutants pre XBB.1.5 adapted vaccine

A)


Geometric mean titer:	1646	94	69	100	276	69	92	84	106	95	262	122	242	230	196	51
Fold reduction (vs. BA.2):	-	18	24	16	6	24	18	20	16	17	6	13	7	7	8	32
Sample number:	30	30	25	20	20	20	20	16	20	20	20	21	21	18	18	20




Neutralisation titers for S1/S2 and S2 specific BA.2.86pp mutants pre XBB.1.5 adapted vaccine

A)

Geometric mean titer:	1646	94	135	110	437	80	108	68
Fold reduction (vs. BA.2):	—	18	12	15	4	21	15	24
Sample number:	30	30	21	21	20	22	20	20



B)



Neutralisation titers for BA.2.86pp mutants post XBB.1.5 adapted vaccine

